Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma
Lipiodol
Clinical endpoint
Transcatheter arterial chemoembolization
DOI:
10.1097/meg.0b013e328346d505
Publication Date:
2011-04-30T05:09:11Z
AUTHORS (10)
ABSTRACT
Objective Lipiodol transcatheter arterial chemoembolization (TACE) is widely used to treat hepatocellular carcinoma (HCC). Recently, a drug-eluting bead (DEB) has been developed enhance drug delivery the tumor and reduce its systemic availability. The purpose of this study was compare efficacy safety intra-arterial injection DEB loaded with doxorubicin versus conventional, Lipiodol-based TACE regimens in Asian patients HCC. Methods designed as case–control, single-institution clinical trial. Twenty HCC who received 50 mg ('cases') were matched 20 had undergone conventional ('controls'). primary endpoint response at 1 month according modified Response Evaluation Criteria Solid Tumors. liver toxicity. Results rate objective by Tumors 85% (17 patients) arm 30% (six (P=0.001). Subgroup analyses conducted large (>5 cm) or multinodular confirmed significantly higher rates receiving compared those treated (P=0.003 P=0.005, respectively). At dose doxorubicin, there no statistically significant difference toxicity between (P>0.05). Conclusion In HCC, treatment offers distinct advantage regimens.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (1)
CITATIONS (54)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....